View Cart  
Fdanewsdrugdailybulletin

Feb. 25, 2005

Vol. 2 No. 40

View Archived Issues

Sign Up Now

House Bill Would Prevent Political Tampering With Federal Research

A pair of prominent House Democrats has introduced legislation that would prevent government officials from tampering with federal research and scientific policymaking.

Read More

Teva May Gain Marketing Exclusivity for 26 Products

Teva Pharmaceutical's U.S. generic pipeline currently consists of 140 product applications, 26 of which it hopes to gain marketing exclusivity for, the company said in its fourth-quarter earnings report.

Read More

Expert Says Medicare Rx Formularies Are Minimalist

Despite assurances that all medically necessary drugs must be made available under the Medicare prescription drug benefit, the final guidelines for designing the Rx formularies could still leave numerous drugs off the list, says a pharmaceutical industry expert.

Read More

FDA to Hold Public Workshop on Clinical Trial Requirements

The FDA is holding a two-day workshop in April to discuss statutory and regulatory requirements for clinical trials.

Read More

Abatement of Excise on Drugs Raised

Conceding to the industry's demand, the government hiked the abatement limit of excise duty on the retail price of drugs to 40 percent from 35 percent at present.

Read More

Pfizer Acquires Idun Pharmaceuticals

Pfizer has acquired San Diego-based Idun Pharmaceuticals, a company focused on discovery and development of therapeutics in the area of liver disease, inflammation and cancer.

Read More

AIDS Drug Factory for CEMAC Countries

A factory in Gabon will produce six types of generic antiretroviral drugs for people living with AIDS.

Read More

Shire Faces New Adderall Threat

Shire Pharmaceuticals is facing a new generic challenge to its key Adderall XR drug from Israel-based drug concern Teva Pharmaceutical.

Read More

Torrent Pharma and AstraZeneca Sign R&D Pact

Torrent Pharmaceuticals has signed a research collaboration agreement with the U.S.-based AstraZeneca.

Read More

Curacyte AG and IBFB Pharma Announce Merger

Curacyte AG, a late stage drug discovery and development company has announced its merger with IBFB PHARMA GmbH. IBFB PHARMA is a biopharmaceutical company engaged in discovery and development of therapeutics to treat a variety of inflammatory diseases.

Read More

Alpharma Announces Development and Manufacturing Agreement With Orchid

Alpharma has entered into an agreement with Orchid Chemicals & Pharmaceuticals, a Chennai-based global pharmaceutical company, whereby Orchid will develop, manufacture and supply generic prescription products for exclusive sale by Alpharma.

Read More

Shire CEO Believes Canada Will Reverse Drug Ban

Shire Pharmaceuticals Group Plc is confident Canadian regulators will reverse a decision to suspend its top-selling hyperactivity drug, since the ban is not justified, the company's chief executive has said.

Read More

Prolexys Pharmaceuticals Licenses Novel Anticancer Compounds

Prolexys Pharmaceuticals, a biopharmaceutical company dedicated to the development of novel cancer therapies, has signed an exclusive licensing agreement with the Massachusetts Institute of Technology, acting as licensing agent for the Whitehead Institute for Biomedical Research of Cambridge, Mass., and Columbia University of New York City.

Read More